Diligence memo · auto-generated · as of July 2, 2026
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Sensorium Therapeutics, Inc. operates in Pharmaceuticals, based in MEDFORD.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sensorium Therapeutics, Inc. has raised $60M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $27M on 2025-01-28.
Most recent recorded round closed around 2025-01-28.
Valuation (modeled)modeled
Provath models Sensorium Therapeutics, Inc. at approximately $149M (range $56M–$239M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.34× the median modeled value of Series B Pharmaceuticals companies in 2025–2027 (17 peers) — value vs value, same stage and era. Within the normal band (134% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 17 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 1.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 84% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 63% of those peers.
Closest niche peers: Phlow Corp., AlphaTON Capital Corp, Triton Therapeutics, Inc., Belhaven Biopharma Inc., AN2 Therapeutics, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.